Skip to main content
. Author manuscript; available in PMC: 2021 Apr 14.
Published in final edited form as: Med. 2021 Feb 23;2(4):395–410. doi: 10.1016/j.medj.2021.01.002

Figure 2: 13C labeling in tumor metabolites from two children with neuroblastoma.

Figure 2:

(A) Expected labeling of glycolytic and TCA cycle metabolites after infusion with [U-13C]glucose. In this scheme, the two labeled carbons from acetyl-CoA are transferred to citrate positions 1 and 2 and then to positions 4 and 5 of α-KG and carried further around the TCA cycle. Labeled OAA exchanges with labeled aspartate. Further metabolism of labeled OAA into subsequent turns of cycle is not illustrated.

(B) Computed tomography of Patient #1, a 9-year old boy with a non-MYCN-amplified neuroblastoma (red box).

(C) Time-dependent labeling of glucose, lactate and pyruvate in Patient #1’s plasma during the [U-13C]glucose infusion.

(D) Labeling in metabolites extracted from Patient #1’s tumor. Labeling is normalized to the glucose m+6 fraction in plasma at the time of tumor resection.

(E) Computed tomography of Patient #3, a 2-year old girl with a non-MYCN-amplified neuroblastoma (red box).

(F) Time-dependent labeling of glucose, lactate and pyruvate in Patient #3’s plasma during the [U-13C]glucose infusion.

(G) Labeling in metabolites extracted from Patient #3’s tumor. Labeling is normalized to the glucose m+6 fraction in plasma at the time of tumor resection.